Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Lymphatics
Special Issues
Advances in Lymphoid Disorders: Immunological Insights and Therapeutic Innovations
share announcement

Advances in Lymphoid Disorders: Immunological Insights and Therapeutic Innovations

A special issue of Lymphatics (ISSN 2813-3307).

Deadline for manuscript submissions: closed (31 October 2025) | Viewed by 2091

Special Issue Editor

Dr. Nabiha Yusuf

E-Mail Website
Guest Editor
Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Interests: interferons; cancer; innate immunity; adaptive immunity; skin; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lymphoid disorders refer to diseases that affect the lymphoid system, which includes lymph nodes, spleen, thymus, bone marrow, and lymphoid tissues associated with mucosal surfaces. These disorders can be broadly classified into benign (non-cancerous) and malignant (cancerous) conditions. Advances in lymphoid disorders, including lymphomas, leukemias, and other immune-related malignancies, have been significant in recent years. The landscape of lymphoid disorders is rapidly evolving with breakthroughs in personalized medicine, improving patient survival and quality of life. The future holds promise for even more refined, less toxic, and highly effective treatment options, thanks to advances in diagnostics, targeted therapies, immunotherapies, bone marrow transplantation, liquid biopsies for disease monitoring, and our understanding of disease biology, among others.

This Special Issue is expanding current knowledge on advances in lymphoid disorders. Experimental studies in in vivo models, review articles, and clinical studies are all welcome for publication.

Dr. Nabiha Yusuf
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Lymphatics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lymphoid disorders
  • immunotherapy
  • therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

33 pages, 751 KB  
Review
Rewiring the Lymphatic Landscape: Disorders, Remodeling, and Cancer Progression
by Sudeep Kumar, Ujjwal Adhikari and Brijendra Singh
Lymphatics 2025, 3(4), 37; https://doi.org/10.3390/lymphatics3040037 - 18 Nov 2025
Viewed by 635
Abstract
The lymphatic system is essential for maintaining the body’s fluid balance, lipid absorption, and immune regulation. The dysfunction of the lymphatic system is associated with a wide spectrum of disorders. These disorders include primary and secondary lymphedema, congenital malformations, and lymphatic neoplasms. In [...] Read more.
The lymphatic system is essential for maintaining the body’s fluid balance, lipid absorption, and immune regulation. The dysfunction of the lymphatic system is associated with a wide spectrum of disorders. These disorders include primary and secondary lymphedema, congenital malformations, and lymphatic neoplasms. In cancer patients, lymphatic remodeling is essential, which facilitates tumor progression and metastasis, while tertiary lymphoid structures (TLSs) develop during chronic inflammation and may be involved in anti-tumor immunity. This review highlights the immunological basis of lymphatic disorders, with a particular focus on cellular and molecular biomarkers that define disease states. The recent advances in molecular imaging techniques, such as ultrasonography (US), computed tomography (CT), and magnetic resonance lymphography (MRL), have improved and identified the diagnosis and therapeutic targets for lymphedema. Moreover, nanobiotechnology and nano-delivery tools have further enhanced the visibility of cancer cells by imaging. Artificial Intelligence (AI) in lymphatic systems have offered a new spectrum for disease prediction using forms of AI such as natural language processing (NLP), machine learning (ML), robotics-assisted approaches, fussy model (FM), and natural language processing (NLP)-based algorithms. Collectively, these advanced tools have improved diagnostic approaches and reveal exciting opportunities for future research and new therapeutic developments in patient care. Full article
(This article belongs to the Special Issue Advances in Lymphoid Disorders: Immunological Insights and Therapeutic Innovations)
►▼ Show Figures

Figure 1

43 pages, 2880 KB  
Review
Relevance of AKT and RAS Signaling Pathways for Antibody–Drug Conjugate Immunotherapies in Acute Lymphoblastic Leukemia
by Patrick A. H. Ehm and Christoph Rehbach
Lymphatics 2025, 3(4), 33; https://doi.org/10.3390/lymphatics3040033 - 13 Oct 2025
Viewed by 1129
Abstract
Acute lymphoblastic leukemia is the most common cause of cancer-related death in children and represents a poor prognosis for patients in high-risk groups. Current treatment protocols are based on intensive polychemotherapy, which is associated with a significant toxicity profile. Due to their higher [...] Read more.
Acute lymphoblastic leukemia is the most common cause of cancer-related death in children and represents a poor prognosis for patients in high-risk groups. Current treatment protocols are based on intensive polychemotherapy, which is associated with a significant toxicity profile. Due to their higher specificity and lower toxicity, immunotherapies based on monoclonal antibodies, in particular antibody–drug conjugates (ADCs), are revolutionizing cancer therapy. However, reports on the potential efficacy of ADC-targeted therapy in ALL and its subgroups are limited. Gene expression data suggest that potentially new ADC antigens are highly abundant in ALL subgroups and represent promising targets for cancer therapy. In addition, the PI3K/AKT and RAS/MAPK signaling pathways are often persistently activated in ALL and recent data showed that active feedback loops following inhibition of these pathways can lead to redundancy of cell surface receptors that can potentially serve as antigens for ADC treatment. Therefore, we provide here an overview of the most interesting receptors of the various ALL subgroups and discuss the influence that feedback loops of the PI3K/AKT and RAS/MAPK signaling pathways may have on increasing protein expression of the aforementioned receptors, which could lead to targeted combination therapy approaches in the future. Full article
(This article belongs to the Special Issue Advances in Lymphoid Disorders: Immunological Insights and Therapeutic Innovations)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop